Credit Suisse Downgrades Thoratec (THOR) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/1/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- Short sellers pile into SpaceX ahead of earnings, lockup expiration
- Wall Street ends higher as Amazon soothes AI jitters
- Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Northland Capital Markets Downgrades Thoratec (THOR) to Market Perform
August 11, 2014 7:17 AM EDTNorthland Capital Markets downgraded Thoratec (NASDAQ: THOR) from Outperform to Market Perform with a price target of $26.00 (from $46.00).
Analyst Suraj Kalia said, "THOR Q2 results epitomized poor tactical execution & clinical messaging in the field.... More
BofA/Merrill Lynch Downgrades Thoratec (THOR) to Neutral; Widespread Bad News
August 7, 2014 2:38 PM EDTBofA/Merrill Lynch downgraded Thoratec (NASDAQ: THOR) from Buy to Neutral with a price target of $25.00 (from $41.00), saying the bad news was widespread in Q2.
Analyst Bob Hopkins noted weak LVAD market growth of only 1%, share losses to HTWR, turnover in... More
BTIG Downgrades Thoratec (THOR) to Neutral (Earlier)
August 7, 2014 10:54 AM EDTBTIG downgraded Thoratec (NASDAQ: THOR) from Buy to Neutral. Analyst Sean Lavin said Thoratec 'dropped a bomb' with its large Q2 miss and reduced guidance.
"We are stunned by THORs results and feel the drastic reduction in guidance point to deeper problems than... More
Goldman Sachs Downgrades Thoratec (THOR) to Neutral
August 7, 2014 7:08 AM EDTGoldman Sachs downgraded Thoratec (NASDAQ: THOR) from Buy to Neutral with a price target of $28.00 (from $38.00).
Analyst David H. Roman said, "Given these results and revised forward outlook, we are downgrading shares of Thoratec (THOR) from Buy to Neutral and reduce our... More
Thoratec Corp (THOR) Reports In-Line Q2 EPS, FY14 Guidance Misses Views
August 6, 2014 4:06 PM EDTThoratec Corp (NASDAQ: THOR) reported Q2 EPS of $0.43, in-line with the analyst estimate of $0.43. Revenue for the quarter came in at $118.1 million versus the consensus estimate of $128.3 million.
The HeartMate® product line contributed $102.0 million, a decrease of 12 percent while the CentriMag product line contributed $13.1 million, an increase of... More
